Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03703297 · ClinicalTrials.gov registry record · Phase 3
Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy
A Phase 3 study of Small-cell Lung Cancer, sponsored by AstraZeneca.
- Active
- Registry status
- Phase 3
- Development phase
- 730
- Enrollment target
- 20
- Study locations
NCT03703297: Active Phase 3 study of Small-cell Lung Cancer, sponsored by AstraZeneca.
NCT03703297 is a Phase 3 study of Small-cell Lung Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 730 participants, above the 223-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (227% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03703297, a Phase 3 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by AstraZeneca.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 730 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Primary Outcome
PFS per RECIST 1.1 assessed by BICR was defined as the time from the date of randomization until the date of objective disease progression (PD) or death (by any cause in the absence of progression) regardless of whether the participant withdrew from therapy or received another anticancer therapy prior to progression. PD was defined as at least a 20% increase in the sum of diameters of target lesions (TLs), taking as reference the smallest previous sum of diameters (nadir) - this included the bas
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (20)
Florida
- Research Site - Fort Myers
- Research Site - Orange City
- Research Site - St. Petersburg
Maryland
- Research Site - Annapolis
- Research Site - Baltimore
- Research Site - Towson
Indiana
- Research Site - Fort Wayne
- Research Site - Muncie
Michigan
- Research Site - Detroit
- Research Site - Grand Rapids
Arizona
- Research Site - Tucson
California
- Research Site - Santa Rosa
Connecticut
- Research Site - New Haven
Georgia
- Research Site - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 730 participants |
| Start Date | 2018-09-27 |
| Est. Completion | 2026-10-23 |
| Phase | Phase 3 |
What the registry record for NCT03703297 still lists
NCT03703297 is an interventional study that assigns participants to a tested intervention. The registered 730 participants enrollment target is mid-sized for trials with a published cap, above the 223-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (227% higher).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT03703297 names 20 study sites across 14 states, led by Florida, Maryland, Indiana.
Frequently Asked Questions
What is clinical trial NCT03703297 about?
NCT03703297 is a clinical study titled "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy". This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
What is the current status of trial NCT03703297?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 730 participants. The study started on 2018-09-27. Estimated completion is 2026-10-23.
What conditions does trial NCT03703297 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
What interventions are being tested in trial NCT03703297?
The interventions under investigation include: Placebo (OTHER), Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03703297?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03703297 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03703297's enrollment target sits among peer trials
730 5th of 79 higher than 75 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
RECRUITING · Phase 3
-
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
RECRUITING · Phase 3
-
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
ACTIVE NOT RECRUITING · Phase 3
-
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03232918 · 730 participants · Phase 4
Oxytocin and Fetal Heart Rate Changes
- NCT05548283 · 730 participants · Phase 4
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
- NCT07312162 · 730 participants
Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI